Table 2.

Patient characteristics

			TREATMENT NUMBERS				All Patients
			Regimen-A		Regimen-B
			n	Row %	n	Row %	n	Row %
GENDER	MALE		95	51.1	91	48.9	186	100.0
	FEMALE		67	47.2	75	52.8	142	100.0
RACE	WHITE, NON-HISP		118	49.6	120	50.4	238	100.0
	BLACK, NON-HISP		44	48.9	46	51.1	90	100.0
INSTITUTIONAL DIAGNOSIS	EP		43	52.4	39	47.6	82	100.0
	MB*		48	42.9	64	57.1	112	100.0
	sPNET		24	63.2	14	36.8	38	100.0
	OTHERS		47	49.0	49	51.0	96	100.0
M-STAGE	M0		137	49.3	141	50.7	278	100.0
	M+		25	50.0	25	50.0	50	100.0
INSTITUTIONAL DIAGNOSIS vs. M-STAGE	EP	M0	41	52.6	37	47.4	78	100.0
		M+	2	50.0	2	50.0	4	100.0
	MB*	M0	36	42.4	49	57.6	85	100.0
		M+	12	44.4	15	55.6	27	100.0
	sPNET	M0	19	65.5	10	34.5	29	100.0
		M+	5	55.6	4	44.4	9	100.0
	OTHERS	M0	41	47.7	45	52.3	86	100.0
		M+	6	60.0	4	40.0	10	100.0
SURGERY EXTENT	STR/Biopsy		115	52.0	106	48.0	221	100.0
	GTR		47	43.9	60	56.1	107	100.0
INSTITUTIONAL DIAGNOSIS vs. SURGERY EXTENT	EP	STR/Biopsy	29	55.8	23	44.2	52	100.0
		GTR	14	46.7	16	53.3	30	100.0
	MB*	STR/Biopsy	29	42.6	39	57.4	68	100.0
		GTR	19	43.2	25	56.8	44	100.0
	sPNET	STR/Biopsy	18	64.3	10	35.7	28	100.0
		GTR	6	60.0	4	40.0	10	100.0
	OTHERS	STR/Biopsy	39	53.4	34	46.6	73	100.0
		GTR	8	34.8	15	65.2	23	100.0
All Patients			162	49.4	166	50.6	328	100.0

Abbreviations used: MB, medulloblastoma; EP, ependymoma, sPNET, supratentorial primitive neuroectodermal tumor; STR, subtotal resection; GTR, gross total resection.

*Including the posterior fossa PNETs.